{"id":"W4220799525","doi":"10.1158/1538-7445.sabcs21-gs1-02","title":"Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gemcitabine; Carboplatin; Pembrolizumab; Internal medicine; Taxane; Hazard ratio; Population; Oncology; Placebo; Chemotherapy; Breast cancer; Clinical endpoint; Cancer; Confidence interval; Clinical trial; Cisplatin; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003906744,0.0006102091,0.002435455,0.0007755794,0.0004431456,0.00004356857,0.0007166004,0.0001102911,0.003982546],"category_scores_gemma":[0.0003337371,0.0004670956,0.0003975518,0.001907118,0.0007633756,0.0002460956,0.0001568277,0.001171112,0.000003143559],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001773703,"about_ca_system_score_gemma":0.003694498,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006849037,"about_ca_topic_score_gemma":0.001127013,"domain_scores_codex":[0.9929079,0.0008699847,0.00174549,0.001148056,0.002149857,0.001178654],"domain_scores_gemma":[0.9939176,0.001691165,0.0009143498,0.0009803864,0.002144992,0.0003515392],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9006025,0.00590381,0.00007593008,0.0009085445,0.002535662,0.00004320696,0.009969128,0.002063235,0.005382361,0.00001780171,0.001529416,0.07096846],"study_design_scores_gemma":[0.9487478,0.009857583,0.0003060969,0.0007111226,0.0004192341,0.00006612123,0.004632633,0.0008092924,0.03128275,0.000120765,0.002597635,0.0004489889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9691744,0.00358739,0.0002428409,0.002860586,0.0002840511,0.02139351,0.002237702,0.00007533148,0.0001441609],"genre_scores_gemma":[0.9769852,0.002082645,0.0003825126,0.0002223896,0.0002644504,0.01644774,0.0001306325,0.000185434,0.003299037],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07051947,"threshold_uncertainty_score":0.9997781,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1262927204348393,"score_gpt":0.4541896713619176,"score_spread":0.3278969509270783,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}